Pain Drug Development Pipeline Review, 2017

“The Report Pain Drug Development Pipeline Review, 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. –”

About Pain Drug Market

This report provides an overview of the pain pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Osteoarthritis Pain, Migraine pain and Neuropathic Pain, therefore covering a number of the most difficult-to-treat chronic and acute pain subtypes.

Get Sample copy of this Report @

Osteoarthritis pain is the most common symptom associated with osteoarthritis which causes disruption of the cartilage. This further leads to rubbing of the bones against each other stimulating pain. Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. Finally neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury, in which the nerve fibres could be damaged resulting in the generation of abnormal signals. However, it is exhibited in a range of diseases and has no specific identifiable cause.

The size of these pipelines ranges from 62 products in osteoarthritis pain to 249 in neuropathic pain. Within osteoarthritis pain, prostaglandin G/H synthases 1 and 2 and the nerve growth factor receptors are being studied by the most pipeline products; while the prostaglandin receptors are frequently targeted by already approved marketed products, the nerve growth factor receptors are not.

View Sample PDF @

In migraine, it is the 5-hydroxytryptamine (serotonin) receptors 1D and 1B which are being most frequently studied, again reflecting the composition of the market for this indication. However, the calcitonin gene related peptide and its receptor, also very frequently targeted, are not yet present in the migraine market. Finally, the favoured targets of neuropathic pain are the sodium channel protein type 9 (Nav1.9) and the mu type opioid receptor. While the latter is already heavily targeted in the pain market, the former is not.


– Which companies are the most active within the pipeline for pain therapeutics?

– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

– What are the most important R&D milestones and data publications to have happened in the field of pain therapeutics?

Reasons to buy

– Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

– Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

– Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

– Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

View Report @

Table of Contents

GBI Research Report Guidance 2

Executive Summary 3

Table of Contents 4

List of Tables 5

List of Figures 11

Introduction 12

GBI Research Report Coverage 12

Osteoarthritis Pain – Overview 12

Migraine – Overview 12

Neuropathic Pain – Overview 12

Therapeutics Development 13

Osteoarthritis Pain 13

Migraine 20

Neuropathic Pain 28

Therapeutics Assessment 45

Osteoarthritis Pain 45

Migraine 55

Neuropathic Pain 65

Companies Involved in Therapeutics Development 78

Osteoarthritis Pain 78

Migraine 98

Neuropathic Pain 117

Dormant Projects 177

Osteoarthritis Pain 177

Migraine 179

Neuropathic Pain 182

Discontinued Products 191

Osteoarthritis Pain 191

Migraine 192

Neuropathic Pain 193

Product Development Milestones 196

Osteoarthritis Pain 196

Migraine 206

Neuropathic Pain 217

Appendix 228

Methodology 228

Coverage 228

Secondary Research 228

Primary Research 228

Expert Panel Validation 228

Contact Us 228

Disclaimer 229

Send An Enquiry Request @

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074



Leave a Reply

Designed by
Powered by